Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 33.3%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Gemcitabine vs mitomycin

Time to death from bladder cancer · patients with non‐muscle invasive bladder cancer

The review found no eligible studies for this question.

1 finding from 1 review

Intravesical gemcitabine for non‐muscle invasive bladder cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine vs BCG

Time to death from bladder cancer · participants with recurrent (1‐course BCG failure) high‐risk non‐muscle invasive bladder cancer (49 men, 31 women)Country: Italy

It is very uncertain whether gemcitabine changes time to death from bladder cancer compared with BCG (very low certainty).

1 finding from 1 review

Intravesical gemcitabine for non‐muscle invasive bladder cancer 2021 · Cochrane Headline outcomes only
HR 0.04 [0.01, 2.25]
1 study · 80 participants
Very low

Gemcitabine vs Normal saline

Time to death from bladder cancer · patients with non‐muscle invasive bladder cancer

It is very uncertain whether gemcitabine changes time to death from bladder cancer(absolute effect size estimates… compared with saline (very low certainty).

1 finding from 1 review

Intravesical gemcitabine for non‐muscle invasive bladder cancer 2021 · Cochrane Headline outcomes only
HR 0.98 [0.02, 49.4]
1 study · 328 participants
Very low